pillbase.ru

Harvoni

Active substance: ledipasvir, sofosbuvir

ledipasvir, sofosbuvir

Centralised EU authorisationActive

Marketing holder: Gilead Sciences Ireland UC

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Products containing ledipasvir in other countries

Showing products with this active substance, combinations included; the full composition is shown for each product.

CountryProducts
RU 3
  • Гарвони®
    таблетки, покрытые пленочной оболочкой, 90 мг+400 мг (original in Russian, GRLS)
    ЛП-№(006349)-(РГ-RU)
    Гилеад Сайенсиз Интернешнл Лимитед
  • Гарвони®
    таблетки, покрытые пленочной оболочкой, 90 мг+400 мг (original in Russian, GRLS)
    ЛП-006104
    Гилеад Сайенсиз Интернешнл Лимитед
  • Ледипасоф
    таблетки, покрытые пленочной оболочкой, 90 мг+400 мг (original in Russian, GRLS)
    ЛП-№(006609)-(РГ-RU)
    Акционерное общество "Фармасинтез" (АО "Фармасинтез")
US 5
  • Harvoni
    TABLET, FILM COATED · LEDIPASVIR 90 mg/1, SOFOSBUVIR 400 mg/1
    61958-1801
    Gilead Sciences, Inc
  • Harvoni
    PELLET · LEDIPASVIR 33.75 mg/1, SOFOSBUVIR 150 mg/1
    61958-1805
    Gilead Sciences, Inc
  • Harvoni
    PELLET · LEDIPASVIR 45 mg/1, SOFOSBUVIR 200 mg/1
    61958-1804
    Gilead Sciences, Inc
  • Harvoni
    TABLET, FILM COATED · LEDIPASVIR 45 mg/1, SOFOSBUVIR 200 mg/1
    61958-1803
    Gilead Sciences, Inc
  • Ledipasvir and Sofosbuvir
    TABLET, FILM COATED · LEDIPASVIR 90 mg/1, SOFOSBUVIR 400 mg/1
    72626-2601
    Asegua Therapeutics LLC
Registration
Registration number
EMEA/H/C/003850
Registration status
Active
ATC code
J05AX65
Sources
  • product · EMA · EMEA/H/C/003850 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/003850 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/003850 · Verified 2026-10-09
  • ingredients.1 · EMA · EMEA/H/C/003850 · Verified 2026-10-09